Frontline plc (STO:FROO)

Verve Therapeutics Revenue

Frontline had revenue of $427.87M USD in the quarter ending March 31, 2025, a decrease of -26.03%. This brings the company's revenue in the last twelve months to $1.90B, up 0.88% year-over-year. In the year 2024, Frontline had annual revenue of $2.05B with 13.77% growth.

• Revenue (ttm): $1.90B
• Revenue Growth: +0.88%
• P/S Ratio: 2.13
• Revenue / Employee: $22.35M
• Employees: 85
• Market Cap: 40.57B

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	2.05B	248.20M	13.77%
Dec 31, 2023	1.80B	371.98M	26.01%
Dec 31, 2022	1.43B	680.83M	90.85%
Dec 31, 2021	749.38M	-471.81M	-38.64%
Dec 31, 2020	1.22B	264.56M	27.65%